Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvalent, Inc. filings document a clinical-stage oncology company developing small-molecule inhibitors for clinically proven kinase targets. Its Form 8-K reports disclose operating and financial results, pipeline and clinical-trial updates for zidesamtinib and neladalkib, FDA submission events, material-event disclosures, and royalty or revenue-share arrangements for its investigational product candidates.
Proxy materials cover annual meeting governance, executive compensation, equity awards, and shareholder voting matters. Other disclosures describe Nuvalent's Class A common stock, capital-structure matters, research and development spending, cash resources, and regulatory considerations associated with advancing ROS1-, ALK-, and HER2-directed cancer programs.
Squarer Ron reported acquisition or exercise transactions in this Form 4 filing.
Nuvalent, Inc. director Ron Squarer reported an equity award of Class A Common Stock in the form of restricted stock units. He received 3,444 RSUs, each convertible into one share of Class A Common Stock at no purchase price.
The RSUs vest in full on the earlier of June 16, 2027 or the date of Nuvalent’s next annual meeting of stockholders, as long as Squarer continues to provide service through that date. After this grant, his reported direct holdings total 6,281 shares.
Protopapas Anna reported acquisition or exercise transactions in this Form 4 filing.
Nuvalent, Inc. director Anna Protopapas reported an equity award of 3,444 restricted stock units (RSUs) of Class A Common Stock. The award was recorded at a price of $0.00 per share, reflecting a compensation grant rather than a market purchase or sale.
Each RSU represents the right to receive one share of Nuvalent Class A Common Stock. The RSUs vest in full on the earlier of June 16, 2027 or the date of Nuvalent's next annual meeting of stockholders, subject to her continued service through the vesting date. Following this grant, she holds 8,590 shares directly.
Oliger Christy J. reported acquisition or exercise transactions in this Form 4 filing.
Nuvalent, Inc. director Christy J. Oliger reported a compensation-related equity award of 3,444 shares of Class A Common Stock in the form of restricted stock units (RSUs). These RSUs vest in full on the earlier of June 16, 2027 or Nuvalent’s next annual stockholder meeting, subject to continued service. Following this grant, Oliger reports 7,415 shares of Class A Common Stock, including these RSUs, held directly.
Nuvalent, Inc. director Michael L. Meyers reported an equity grant of 3,444 shares of Class A Common Stock through restricted stock units (RSUs) at no cash cost. Each RSU converts into one share and vests in full on the earlier of June 16, 2027 or Nuvalent’s next annual stockholder meeting, subject to his continued service. Following this award, he holds 8,590 shares directly.
Bogle Grant C. reported acquisition or exercise transactions in this Form 4 filing.
Nuvalent, Inc. director Grant C. Bogle received an equity award of 3,444 restricted stock units (RSUs) of Class A Common Stock. Each RSU represents one share of Class A Common Stock granted at $0.00 per share as compensation, not a market purchase.
The RSUs vest in full on the earlier of June 16, 2027 or Nuvalent’s next annual meeting of stockholders, as long as Bogle continues providing service through that date. After this award, Bogle’s direct holdings reported in this filing total 9,291 shares, including the RSUs.
Nuvalent, Inc. reported the results of its 2026 annual meeting of stockholders held on June 16, 2026. A total of 71,190,894 shares of Class A common stock were represented, about 96.80% of shares outstanding as of the April 20, 2026 record date.
Stockholders elected Class II directors Michael L. Meyers, M.D., Ph.D. and Ron Squarer to three-year terms ending at the 2029 annual meeting. They also approved, on an advisory basis, the compensation of the company’s named executive officers and ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Nuvalent, Inc. Chief Development Officer Darlene Noci reported option exercises and a share sale. On June 9, 2026, she exercised stock options for 20,000 shares of Class A Common Stock at exercise prices of $18.93, $6.89, and $1.08 per share.
On the same date, she sold 20,000 shares in an open-market transaction at an average price of $122.81 per share pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024. Following these transactions, she directly held 58,117 shares of Class A Common Stock.
GSK plc, together with GlaxoSmithKline LLC and acquisition subsidiaries, announced a planned cash tender offer to acquire all issued and outstanding Class A and Class B shares of Nuvalent, Inc. The parties referenced an Agreement and Plan of Merger dated June 9, 2026. The announcement is a pre-commencement communication and the tender offer has not yet commenced. The filing states that when the offer is launched GSK plc, Parent and Purchaser will file a Tender Offer Statement on Schedule TO and Nuvalent will file a Solicitation/Recommendation Statement on Schedule 14D-9. The documents will be made available free on the SEC website and on the companies' investor sites. The communication contains forward-looking statements and directs readers to the "Risk Factors" in GSK plc's Annual Report on Form 20-F for the year ended December 31, 2025.
Nuvalent, Inc. President and CEO James Richard Porter reported an exercise-and-sell transaction involving Class A Common Stock. On June 8, 2026, he sold a total of 30,000 shares in open-market sales at weighted average prices in the high-$80 range, pursuant to a Rule 10b5-1 trading plan adopted on December 4, 2025. On the same date, he exercised stock options for 30,000 shares at an exercise price of $18.93 per share. Following these transactions, he directly holds 324,879 shares of Nuvalent Class A Common Stock and 148,686 stock options with a stated exercise price of $18.93 per share and expiration in 2032.
GSK plc announced a planned cash tender offer to acquire all issued and outstanding Class A and Class B common shares of Nuvalent, Inc. The parties entered into an Agreement and Plan of Merger dated June 9, 2026. The tender offer has not commenced; when it does, the offerors will file a Tender Offer Statement on Schedule TO and the company will file a Solicitation/Recommendation Statement on Schedule 14D-9. Tender offer materials will be made available to Nuvalent stockholders and posted on the SEC website and the parties' investor websites.